Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’

Lignende værker

• Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
  af: Mickisch, G, et al.
  Udgivet: (2010)
• Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
  af: Porta, C
  Udgivet: (2010)
• Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
  af: Mickisch, G H J, et al.
  Udgivet: (2010)
• Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer
  Udgivet: (2015)
• Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
  af: Molina-Garrido, M J, et al.
  Udgivet: (2011)